Literature DB >> 11986233

Interleukin-21 is a growth and survival factor for human myeloma cells.

Anne-Tove Brenne1, Torstein Baade Ro, Anders Waage, Anders Sundan, Magne Borset, Henrik Hjorth-Hansen.   

Abstract

Interleukin-21 (IL-21) is a recently cloned cytokine with homology to IL-2, IL-4, and IL-15. In this study we examined the effects of IL-21 on human myeloma cells. We found that IL-21 induced proliferation and inhibited apoptosis of the IL-6-dependent human myeloma cell lines ANBL-6, IH-1, and OH-2. The potency of IL-21 was close to that of IL-6 in the OH-2 cell line. Neutralizing antibodies to IL-6 or the IL-6 receptor transducer chain (gp130) did not affect IL-21-induced DNA synthesis, indicating that IL-21-induced proliferation was not mediated through these proteins. Tumor necrosis factor (TNF), another stimulator of myeloma cell growth, up-regulated the expression level of IL-21 receptor (IL-21R), and combinations of TNF and IL-21 gave synergistic effects on myeloma cell proliferation. Furthermore, 4 of 9 purified samples of primary myeloma cells showed a significant increase in DNA synthesis on stimulation of the cells by IL-21. By Western blot analysis, we demonstrated that the intracellular signaling pathways of IL-21 in myeloma cells involved phosphorylation of Jak1, Stat3, and Erk1/2 (p44/42 mitogen-activated protein kinase). IL-21 is a novel growth and survival factor in multiple myeloma and may represent a target for future therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986233     DOI: 10.1182/blood.v99.10.3756

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

Review 2.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

3.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

4.  Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.

Authors:  Shweta Jain; Jerrold M Ward; Dong-Mi Shin; Hongsheng Wang; Zohreh Naghashfar; Alexander L Kovalchuk; Herbert C Morse
Journal:  Am J Pathol       Date:  2017-07-17       Impact factor: 4.307

Review 5.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

7.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

8.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

9.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

10.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.